Study on UGT1 A1?6 gene polymorphisms in cancer patients of Han population in Anhui area
10.3969/j.issn.1001-1978.2018.06.023
- VernacularTitle:安徽地区汉族人群肿瘤患者UGT1 A1?6基因多态性分布的差异性研究
- Author:
Jia-Jie LUAN
1
;
Jun LIU
;
Lin WANG
;
Yan-Hong ZHU
;
De-Xi ZHOU
;
Jian ZUO
;
Zhen-Yu XU
Author Information
1. 皖南医学院弋矶山医院药剂科
- Keywords:
UGT1 A1?6;
gene polymorphism;
irino-tecan;
esophageal carcinoma;
adverse drug reaction;
individualized treatment
- From:
Chinese Pharmacological Bulletin
2018;34(6):857-862
- CountryChina
- Language:Chinese
-
Abstract:
Aim To investigate the gene frequency of UGT1 A1?6 in cancer patients in Anhui Han popula-tion. Methods The 222 cases of blood samples of Han cancer patients were collected from different re-gions of Anhui province, and the UGT1A1?6 geno-types were detected by in situ hybridization fluorescencestaining. Results Patients with a UGT1A1?6 wild type ( GG ) accounted for ( 159 cases, 71. 62％) , which were higher than those of heterozygous mutations ( GA, 52 cases, 23. 42％) and of homozygous muta-tions ( AA, 11 cases, 4. 96％) of the total cases. The mutation rate of UGT1 A1?6 was 16. 67％, and partic-ularly in patients with esophageal cancer it was 43. 75％. The rates of mutation in the patients in Ma ' anshan and Chuzhou were 40. 01％ and 34. 62％, re-spectively, both significantly higher than those of othertumors and regions. Conclusions Cancer patients in Anhui Han population have a high mutant frequency of UGT1 A1?6 . The UGT1 A1?6 genotyping can indi-rectly predict the risk of irinotecan's adverse reaction, which obviously enhances the potentially individualized treatment of irinotecan.
